NextCure reports Q1 2022 net loss of $20.6M; cash at $201.3M, runway into Q1 2024

NextCure, Inc.

2022-Q1 EPS reported -$0.74

Net loss of $20.6M vs $16.5M in Q1 2021, driven by higher R&D expenses.
Cash, cash equivalents and securities of $201.3M, down $18.3M from Dec 2021.
On track for H2 2022 milestones: NC318 Phase 2 update, NC410 Phase 1 update, NC762 initial data, NC525 IND filing.
Cash expected to fund operations into Q1 2024.
R&D expenses $15.0M (Q1 2022) vs $12.4M (Q1 2021); G&A $5.8M vs $4.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.